Santhera Announces Approval in Canada for AGAMREE® ( Vamorolone ) as a Treatment for Duchenne Muscular Dystrophy
Pratteln, Switzerland, October 3, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) today notes that Health Canada has approved AGAMREE® ( vamorolone ) for the treatment of Duchenne muscular dystrophy ( DMD ) in patients aged 4 years and older following Priority Review, marking the first approved ...
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
CORAL GABLES, Fla., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and ...
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
Ad hoc announcement pursuant to Art. 53 LR ...
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
Ad hoc announcement pursuant to Art. 53 LR ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Catalyst Pharmaceutical ( CPRX ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How Is The Market Feeling About Catalyst Pharmaceuticals? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has fallen 3.12% since its last report. The company recently reported that it has 8.94 million shares sold short, which is 9.33% of all regular shares that are available for trading.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalyst Pharmaceuticals President and CEO Trades $473K In Company Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Revealing a significant insider sell on August 28, Richard J Daly, President and CEO at Catalyst Pharmaceuticals CPRX, as per the latest SEC filing. What Happened: Daly's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 22,970 shares of ...
Director At Catalyst Pharmaceuticals Sells $525K Of Stock - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
David S Tierney, Director at Catalyst Pharmaceuticals CPRX, executed a substantial insider sell on August 28, according to an SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Tierney sold 26,000 shares of Catalyst Pharmaceuticals.
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® ( Vamorolone ) in India
Pratteln, Switzerland, 29 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Ikris Pharma Network ( Ikris ) to manage the distribution of AGAMREE® ( vamorolone ) in India, for the treatment of Duchenne muscular dystrophy ( DMD ) in patients ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February ...
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend
New York, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- This September, the Muscular Dystrophy Association ( MDA ) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its 75th anniversary.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
CORAL GABLES, Fla., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) CPRX, a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat ...
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® ( amifampridine ) Patent Litigation with Lupin Pharmaceuticals
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February ...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® ( Vamorolone ) in five GCC ( Gulf Cooperation Council ) Countries
Pratteln, Switzerland, 19 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® ( vamorolone ) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment ...
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Santhera extends Highbridge convertible bond to 30th September 2025
Ad hoc announcement pursuant to Art. ...
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® ( Vamorolone ) in Türkiye
Pratteln, Switzerland, 13 August, 2025 - Santhera Pharmaceuticals ( SIX: SANN ) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. ( GEN ) for the distribution and promotion of AGAMREE® ( vamorolone ) in Türkiye for the treatment of Duchenne ...
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Lambert Eaton Myasthenic Syndrome ( LEMS ) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer ( SCLC )
CORAL GABLES, Fla., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) , a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and ...
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Are Investors Undervaluing Catalyst Pharmaceuticals ( CPRX ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 9.1% since its last report. The company recently reported that it has 8.92 million shares sold short, which is 9.35% of all regular shares that are available for trading.
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Rising Cash Flows Make These 4 Stocks Worth Choosing Now
CPRX, STKL, GAMB and ORN are gaining attention as rising cash flows signal strength, flexibility and growth potential.
Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns
Let's take a look at four stocks, CPRX, GAMB, ORN and BWAY, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET ...
Here's Why Catalyst Pharmaceutical ( CPRX ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Should Value Investors Buy Catalyst Pharmaceuticals ( CPRX ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Peering Into Catalyst Pharmaceuticals's Recent Short Interest - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 5.8% since its last report. The company recently reported that it has 8.17 million shares sold short, which is 8.57% of all regular shares that are available for trading.
Why Catalyst Pharmaceutical ( CPRX ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Catalyst Pharmaceutical ( CPRX ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing Catalyst Pharmaceuticals ( CPRX ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Catalyst Pharmaceuticals Gaining or Losing Market Support? - Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Catalyst Pharmaceuticals's CPRX short percent of float has risen 5.19% since its last report. The company recently reported that it has 7.73 million shares sold short, which is 8.1% of all regular shares that are available for trading.
Top 3 Health Care Stocks You'll Regret Missing This Quarter - Catalyst Pharmaceuticals ( NASDAQ:CPRX ) , Moleculin Biotech ( NASDAQ:MBRX )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
